Washington Trust Advisors Inc. Has $366,000 Position in Amgen Inc. (NASDAQ:AMGN)

Washington Trust Advisors Inc. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,405 shares of the medical research company’s stock after purchasing an additional 70 shares during the quarter. Washington Trust Advisors Inc.’s holdings in Amgen were worth $366,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Talbot Financial LLC boosted its holdings in shares of Amgen by 5.6% in the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company’s stock valued at $11,153,000 after buying an additional 2,274 shares during the period. Swiss National Bank boosted its holdings in shares of Amgen by 0.3% in the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company’s stock valued at $513,033,000 after buying an additional 5,500 shares during the period. Asset Advisors Investment Management LLC boosted its holdings in shares of Amgen by 9.0% in the third quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company’s stock valued at $11,578,000 after buying an additional 2,954 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Amgen by 6.0% in the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company’s stock valued at $204,659,000 after buying an additional 35,785 shares during the period. Finally, Ascent Wealth Partners LLC boosted its holdings in shares of Amgen by 0.7% in the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company’s stock valued at $2,352,000 after buying an additional 64 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares in the company, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock worth $20,644,335 in the last quarter. 0.69% of the stock is owned by corporate insiders.

Amgen Stock Up 1.4 %

Amgen stock opened at $316.57 on Thursday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a 50 day moving average price of $283.80 and a two-hundred day moving average price of $299.78. The firm has a market cap of $170.06 billion, a price-to-earnings ratio of 41.93, a PEG ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.01%. Amgen’s dividend payout ratio is currently 126.09%.

Analysts Set New Price Targets

AMGN has been the subject of several recent research reports. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. UBS Group restated a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Truist Financial reduced their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Royal Bank of Canada restated an “outperform” rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Finally, Wolfe Research assumed coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $314.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.